Semaglutide vs Tirzepatide: The Clinical Evidence on Weight Loss, Diabetes, and Side Effects

A long-stay expat based in Chalong walked in recently with a question that comes up often in weight management consultations. Six months on semaglutide, reasonable results, then a friend mentioned tirzepatide produces more weight loss. Was it worth switching? That is not a simple yes or no. Both drugs are available in Thailand, both require a prescription, and the difference between them is real enough to matter clinically.

These are not interchangeable medications with slightly different brand names. Semaglutide acts on one receptor. Tirzepatide acts on two. That changes the numbers in the trials and it changes the decisions. Here is what the evidence actually shows.

One Receptor vs Two: What Each Drug Actually Does

Your body releases hormones after a meal that tell the pancreas to produce insulin and signal the brain to reduce appetite. Semaglutide mimics one of these hormones: GLP-1. Tirzepatide mimics two: GLP-1 and GIP.

GIP appears to enhance the appetite and fat-storage signals in a way that adds to the weight loss effect. The result is a dual incretin agonist that produces meaningfully more weight loss in trials than a GLP-1 agonist alone. That is what SURMOUNT-5 showed directly.

SURMOUNT-5: What the Head-to-Head Trial Actually Showed

SURMOUNT-5 was a randomised trial comparing tirzepatide and semaglutide directly in adults with obesity or overweight without type 2 diabetes. At 72 weeks, tirzepatide produced a mean body weight reduction of 20.2% versus 13.7% with semaglutide. That gap is clinically meaningful, not marginal.

The secondary endpoints matter too. Just over 31% of tirzepatide patients lost 25% or more of their body weight, compared to about 16% of semaglutide patients. Waist circumference reduction was also greater with tirzepatide.

One caveat: SURMOUNT-5 was open-label, meaning patients and investigators knew which drug was being used. That can introduce bias. It does not invalidate the results, but the headline figures should be read as directionally strong rather than definitive.

Real-World Data Beyond the Trial Setting

A 2025 real-world observational study (SHAPE) followed patients on both drugs outside of trial settings and found that both produced meaningful weight loss, with tirzepatide producing greater loss at 12 months. A 2025 meta-analysis across more than 28,000 patients found the same directional pattern.

Real-world evidence does not control variables the way a trial does. But when the real-world data and the trial data point the same way, the signal is harder to dismiss. Tirzepatide consistently produces more weight loss. Whether that difference matters for your situation is the clinical question.

Type 2 Diabetes and Blood Sugar Control

Both drugs are approved for type 2 diabetes management and both reduce HbA1c, your three-month average blood sugar level. Tirzepatide trials in people with type 2 diabetes showed greater HbA1c reductions than those seen with semaglutide in separate trials, though a direct head-to-head comparison in a type 2 diabetes population is more limited than in the obesity trials.

For patients managing type 2 diabetes while living or staying in Phuket, the practical question is often continuity: whether to start, maintain, or adjust a prescription here. That is something a physician can assess directly, including reviewing your most recent results from a blood test in Phuket.

Cardiovascular Evidence: Two Different Trials

Semaglutide has the SELECT trial: a large cardiovascular outcomes study in adults with obesity and established cardiovascular disease but without type 2 diabetes. SELECT showed a 20% reduction in major adverse cardiovascular events compared to placebo. This is robust, prospective, outcomes-level evidence.

Tirzepatide has the SUMMIT trial, which showed cardiovascular benefit in a different population: patients with heart failure with preserved ejection fraction and obesity. The two trials studied different populations with different endpoints and cannot be directly compared.

If your primary concern is cardiovascular risk reduction rather than weight alone, semaglutide currently has the stronger and more directly applicable evidence for that indication. That conversation is worth having with a physician before you choose.

Side Effects and How to Manage Them in Phuket’s Heat

Both drugs cause gastrointestinal side effects during dose escalation: nausea, vomiting, diarrhoea, constipation. These are not rare. For most patients they are worst in the first few weeks on each new dose and settle with time.

In SURMOUNT-5, discontinuation due to gastrointestinal adverse events was 2.7% with tirzepatide and 5.6% with semaglutide. Serious adverse events were slightly higher with tirzepatide (4.8% vs 3.5%), though the trial was not powered to detect a statistically meaningful safety difference between the two drugs.

Eat smaller meals during dose escalation and stay well hydrated. In Phuket’s heat, dehydration from vomiting or diarrhoea compounds faster than patients from cooler climates expect. If you cannot keep fluids down, that warrants same-day review. IV therapy at Takecare Clinic Phuket is available for rehydration when oral intake is not holding.

Who Should Not Use These Medications

Neither drug is appropriate for everyone. Both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Both should be used with caution in patients with a history of pancreatitis. Neither is approved for use in pregnancy.

If you are already on insulin or other glucose-lowering medications, starting either drug requires a physician to review and adjust your regimen. Dropping blood glucose too quickly is a real risk when these medications are added without adjusting existing treatment.

Getting Started or Continuing Treatment in Phuket

Neither medication should be started without a proper clinical assessment. That means reviewing your BMI, current medications, relevant history, and baseline blood tests. Dose escalation, monitoring for response, and managing side effects all require ongoing physician oversight.

Tourists on a short stay are generally not the right candidates for starting a new prescription here. The escalation period requires follow-up. Long-stay visitors, expats, and residents based in areas like Rawai, Bang Tao, or Chalong are better positioned to begin and maintain treatment. If you are already on semaglutide or tirzepatide from a prescription elsewhere, a prescription refill in Phuket is possible after a physician reviews your current treatment. An English-speaking doctor in Phuket at Takecare Clinic Phuket can do this without an appointment. Bring your current medication and any recent blood work, and the consultation takes it from there.